PuraPharm Announces Board Composition and Roles
I'm PortAI, I can summarize articles.
PuraPharm Corp. Ltd. has announced its board composition and roles, clarifying its governance structure, which may influence its strategic direction and reassure stakeholders. The latest analyst rating for PuraPharm (HK:1498) is a Hold with a price target of HK$0.50. The company, based in the Cayman Islands, operates in the pharmaceutical sector, focusing on Chinese medicine products. Current market cap stands at HK$163.9M with an average trading volume of 184,991.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments